Clinial trials:

Clinical trials, where ONCOXIN Oral Solution was associated with chemotherapy and radiotherapy, showed a the patients’ quality of life of the following:

• The quality of life improves significantly. Depressions and difficulties decrease
• Patients’ trust in the effectiveness of the treatment increases.
• Patients show greater resistance to the oncologic treatment, as the frecuency and intensity of side effects drop significantly.
• Increased tolerance to chemotherapy and radiotherapy has been observed gradually throughout the research, thus preventing the interruption of the treatment.
• Decreased intensity od skin erythema, dysphagia, mucus and other types of erythema caused by radiotherapy
• Episodes of leukopenia are much less frequent, and even absent in the group treated with ONCOXIN Oral Solution.
• The Karnofsky Index remains stable after 12 months of the treatment in 87% of the patients treated with ONCOXIN Oral Solution, compared with 47% of the patients who did not take it.
• Weight evolves clearly in the patients given ONCOXIN Oral Solution as compared with the patients who were not.
• Increased quality of life within 10 days, even for terminal patients.
  

Article ONCOXIN Solution (neoplastic diseases).BANGLADESH. (Dec 2009). Download PDF.